Dr. Lawrence Boise’s summary of basic research at #IMS26 included a deep learning classifier for malignant plasma cells, whole proteomics insights into IMiD/CELMoD resistance, an AI-designed trispecific & transmitophagy in MM cells.
September 26, 2026 at 4:52 PM
Dr. Lawrence Boise’s summary of basic research at #IMS26 included a deep learning classifier for malignant plasma cells, whole proteomics insights into IMiD/CELMoD resistance, an AI-designed trispecific & transmitophagy in MM cells.
CRBN mutations in myeloma patients affect IMiD response, but some can still benefit from novel CELMoD treatments.
by Chrisochoidou Y, Scarpino A (...) Pawlyn C et 7 al. in Blood #MedSky
📖 read the article:
by Chrisochoidou Y, Scarpino A (...) Pawlyn C et 7 al. in Blood #MedSky
📖 read the article:
Evaluating the impact of CRBN mutations on response to immunomodulatory drugs and novel CRBN-binding agents in myeloma
Key Points. CRBN missense mutations identified in patients were modelled to explore their effect on CRBN function with IMiD and CELMoD therapy.Mutations le
ashpublications.org
January 31, 2025 at 12:49 PM
CRBN mutations in myeloma patients affect IMiD response, but some can still benefit from novel CELMoD treatments.
by Chrisochoidou Y, Scarpino A (...) Pawlyn C et 7 al. in Blood #MedSky
📖 read the article:
by Chrisochoidou Y, Scarpino A (...) Pawlyn C et 7 al. in Blood #MedSky
📖 read the article:
📊 2026-09-27
• Ocean Cleanup: Nearly Pristine Palmyra Atoll Reefs Offer a Restoration Blueprint — as California Vetoes New Plastic-Fund Spending Rules
• Cancer Breakthroughs: FDA Approves Zenbexus (Iberdomide), First-Ever CELMoD Therapy, in Historic First Oncology Approval Based…
🔗 watchboard.dev
• Ocean Cleanup: Nearly Pristine Palmyra Atoll Reefs Offer a Restoration Blueprint — as California Vetoes New Plastic-Fund Spending Rules
• Cancer Breakthroughs: FDA Approves Zenbexus (Iberdomide), First-Ever CELMoD Therapy, in Historic First Oncology Approval Based…
🔗 watchboard.dev
September 27, 2026 at 3:47 AM
📊 2026-09-27
• Ocean Cleanup: Nearly Pristine Palmyra Atoll Reefs Offer a Restoration Blueprint — as California Vetoes New Plastic-Fund Spending Rules
• Cancer Breakthroughs: FDA Approves Zenbexus (Iberdomide), First-Ever CELMoD Therapy, in Historic First Oncology Approval Based…
🔗 watchboard.dev
• Ocean Cleanup: Nearly Pristine Palmyra Atoll Reefs Offer a Restoration Blueprint — as California Vetoes New Plastic-Fund Spending Rules
• Cancer Breakthroughs: FDA Approves Zenbexus (Iberdomide), First-Ever CELMoD Therapy, in Historic First Oncology Approval Based…
🔗 watchboard.dev
The U.S. Food and Drug Administration (FDA) has approved iberdomide in combination with daratumumab and dexamethasone for patients with relapsed or refractory multiple myeloma — the first approved CELMoD agent for this disease.
Learn how our researchers supported this approval: bit.ly/4wzRCcR
Learn how our researchers supported this approval: bit.ly/4wzRCcR
FDA approves first CELMoD agent, with Dana-Farber helping advance its development
The U.S. Food and Drug Administration has approved iberdomide in combination with daratumumab and dexamethasone for patients with relapsed or refractory multiple myeloma, making it the first approved cereblon E3 ligase modulator (CELMoD) for this disease.
bit.ly
August 14, 2026 at 7:15 PM
The U.S. Food and Drug Administration (FDA) has approved iberdomide in combination with daratumumab and dexamethasone for patients with relapsed or refractory multiple myeloma — the first approved CELMoD agent for this disease.
Learn how our researchers supported this approval: bit.ly/4wzRCcR
Learn how our researchers supported this approval: bit.ly/4wzRCcR
#CELMoD stands for "cereblon E3 ligase modulators". These are targeted protein degraders that use our cells' 'trash can' - the proteasome, to degrade & get rid of proteins with roles in driving malignancy. Exciting news for #MultipleMyeloma - #Zenbexus #iberdomide. 🧪
www.drugs.com/medical-answ...
www.drugs.com/medical-answ...
www.drugs.com
August 21, 2026 at 1:47 AM
#CELMoD stands for "cereblon E3 ligase modulators". These are targeted protein degraders that use our cells' 'trash can' - the proteasome, to degrade & get rid of proteins with roles in driving malignancy. Exciting news for #MultipleMyeloma - #Zenbexus #iberdomide. 🧪
www.drugs.com/medical-answ...
www.drugs.com/medical-answ...
#MultipleMyeloma is an incurable blood cancer. This month a new class of drug has been FDA-approved to enter the therapeutic mix for adults under certain conditions - #Zenbexus (iberdomide) from Bristol-Myers Squibb, a specific targeted protein degrader, #CELMoD 🧪.
www.fda.gov/drugs/resour...
www.fda.gov/drugs/resour...
FDA grants accelerated approval to iberdomide with daratumumab and hya
On August 13, 2026, the Food and Drug Administration granted accelerated approval to iberdomide (Zenbexus, Bristol-Myers Squibb Company) in combination with daratumumab and hyaluronidase-fihj and dexa...
www.fda.gov
August 21, 2026 at 1:31 AM
#MultipleMyeloma is an incurable blood cancer. This month a new class of drug has been FDA-approved to enter the therapeutic mix for adults under certain conditions - #Zenbexus (iberdomide) from Bristol-Myers Squibb, a specific targeted protein degrader, #CELMoD 🧪.
www.fda.gov/drugs/resour...
www.fda.gov/drugs/resour...
Multiple myeloma that resists treatment used to leave few options. Now, FDA approved iberdomide, a new CELMoD drug. It more than doubled the rate of deep remission (MRD-negative complete response) to 41% vs. 21% for standard care in Phase 3. Big difference.
FDA Grants Accelerated Approval to Iberdomide for Relapsed/Refractory Multiple Myeloma
The FDA has given accelerated approval to iberdomide (Zenbexus) in combination with daratumumab and dexamethasone for adults with multiple myeloma that has returned or is resistant to previous treatme
www.fda.gov
August 18, 2026 at 2:03 AM
Multiple myeloma that resists treatment used to leave few options. Now, FDA approved iberdomide, a new CELMoD drug. It more than doubled the rate of deep remission (MRD-negative complete response) to 41% vs. 21% for standard care in Phase 3. Big difference.
BMS's oral CELMoD more than halves myeloma progression #BMY #ASCO26 firstwordpharma.com/story/7487148
May 29, 2026 at 12:14 PM
BMS's oral CELMoD more than halves myeloma progression #BMY #ASCO26 firstwordpharma.com/story/7487148
The FDA granted accelerated approval to the first cereblon E3 ligase modulation therapy for relapsed or refractory multiple myeloma, the agency announced on Thursday.
https://www.medpagetoday.com/hematologyoncology/myeloma/122608
https://www.medpagetoday.com/hematologyoncology/myeloma/122608
FDA Approves First CELMoD Drug for Multiple Myeloma
Iberdomide indicated as part of combination regimen for relapsed or refractory disease
www.medpagetoday.com
August 14, 2026 at 1:19 PM
The FDA granted accelerated approval to the first cereblon E3 ligase modulation therapy for relapsed or refractory multiple myeloma, the agency announced on Thursday.
https://www.medpagetoday.com/hematologyoncology/myeloma/122608
https://www.medpagetoday.com/hematologyoncology/myeloma/122608
CRBN mutations in myeloma can hinder IMiD effectiveness, but novel CELMoDs may still offer therapeutic benefits for affected patients.
by Chrisochoidou Y, Scarpino A (...) Pawlyn C et 7 al. in Blood #MedSky
👉 get more here
📖 read the article:
by Chrisochoidou Y, Scarpino A (...) Pawlyn C et 7 al. in Blood #MedSky
👉 get more here
📖 read the article:
Evaluating the impact of CRBN mutations on response to immunomodulatory drugs and novel cereblon E3 ligase modulators in myeloma
Key PointsCRBN missense mutations identified in patients were modeled to explore their effect on CRBN function with IMiD and CELMoD therapy.Mutations led t
ashpublications.org
June 7, 2025 at 2:17 AM
Golcadomide (CELMoD)+RCHOP 1L LBCL @Lymphoma_Doc #ASH24:
- randomized to 0.2 vs 0.4 mg in dose expansion
- 1-yr PFS 85% at 0.4 mg (77% at 0.2)
- 90% EOT MRD- at 0.4 (73% at 0.2)
- better EOT MRD- with 0.4 mg across high-risk genetics
GOLSEEK-1 RCT ongoing with 0.4 mg dose. #lymsm
- randomized to 0.2 vs 0.4 mg in dose expansion
- 1-yr PFS 85% at 0.4 mg (77% at 0.2)
- 90% EOT MRD- at 0.4 (73% at 0.2)
- better EOT MRD- with 0.4 mg across high-risk genetics
GOLSEEK-1 RCT ongoing with 0.4 mg dose. #lymsm
November 18, 2024 at 2:58 PM
What we heard this week ⬇️👀 #MedSky
"I realize we're close to beer time here -- promise to at least give you something very scintillating." -- Paul Richardson, MD, before presenting trial results for a novel oral drug for #multiplemyeloma at #ASCO26.
www.medpagetoday.com/meetingcover...
"I realize we're close to beer time here -- promise to at least give you something very scintillating." -- Paul Richardson, MD, before presenting trial results for a novel oral drug for #multiplemyeloma at #ASCO26.
www.medpagetoday.com/meetingcover...
CELMoD Drug Cuts Risk of Myeloma Progression, Death by 52% in Trial
Oral mezigdomide's benefit shown in patients mostly refractory to lenalidomide and anti-CD38
www.medpagetoday.com
June 8, 2026 at 4:02 PM
What we heard this week ⬇️👀 #MedSky
"I realize we're close to beer time here -- promise to at least give you something very scintillating." -- Paul Richardson, MD, before presenting trial results for a novel oral drug for #multiplemyeloma at #ASCO26.
www.medpagetoday.com/meetingcover...
"I realize we're close to beer time here -- promise to at least give you something very scintillating." -- Paul Richardson, MD, before presenting trial results for a novel oral drug for #multiplemyeloma at #ASCO26.
www.medpagetoday.com/meetingcover...
Wed news: FDA reverses course on Moderna flu vaccine. Novartis heads to FDA with Rhapsido. Medtronic completes first US Hugo case. How AI could affect pharma jobs. FDA starts review of BMS's 'celmod' for multiple myeloma. —https://bit.ly/3JeBlY5
February 18, 2026 at 5:16 PM
Wed news: FDA reverses course on Moderna flu vaccine. Novartis heads to FDA with Rhapsido. Medtronic completes first US Hugo case. How AI could affect pharma jobs. FDA starts review of BMS's 'celmod' for multiple myeloma. —https://bit.ly/3JeBlY5
🔷 This marks the first positive Phase III trial for the oral CELMoD Mezigdomide, with a safety profile consistent with prior studies.
🔗 Read more: bit.ly/ONCOnews10Ma...
#ONCOnews #OncoAlert #OncEd #MultipleMyeloma #Hematology #Oncology #CancerResearch #ClinicalTrials #Phase3Trial
🔗 Read more: bit.ly/ONCOnews10Ma...
#ONCOnews #OncoAlert #OncEd #MultipleMyeloma #Hematology #Oncology #CancerResearch #ClinicalTrials #Phase3Trial
ONCOassist Universal Link
Opening ONCOassist app...
bit.ly
March 10, 2026 at 2:06 PM
🔷 This marks the first positive Phase III trial for the oral CELMoD Mezigdomide, with a safety profile consistent with prior studies.
🔗 Read more: bit.ly/ONCOnews10Ma...
#ONCOnews #OncoAlert #OncEd #MultipleMyeloma #Hematology #Oncology #CancerResearch #ClinicalTrials #Phase3Trial
🔗 Read more: bit.ly/ONCOnews10Ma...
#ONCOnews #OncoAlert #OncEd #MultipleMyeloma #Hematology #Oncology #CancerResearch #ClinicalTrials #Phase3Trial
#obesity #type2diabetes #rarediseases #cancer #oncology #womenshealth #NovoNordisk #EliLilly #Lilly #GSK #severeasthma #JnJ #biologics #Otsuka #IgAN #kidneydisease #Sanofi #MS #BeOneMedicines #CLL #SLL #BMS #CELMoD #multiplemyeloma #Pfizer #breastcancer #CorceptTherapeutics #SGRA
zurl.co/xauLJ
zurl.co/xauLJ
11 high-impact drugs to look out for in 2026
Medicines for obesity, diabetes, rare diseases, cancer, and women's health feature among Clarivate's annual round-up of 11 Drugs to Watch this year.
pharmaphorum.com
January 27, 2026 at 9:37 AM
Research from @danafarber.bsky.social helped support this month's FDA approval of Iberdomide-based therapy in relapsed/refractory multiple myeloma #mmsm #oncology www.onclive.com/view/fda-app...
FDA Approves First CELMoD Agent, With Dana-Farber Helping Advance Its Development | OncLive
Dana-Farber research aided in the FDA approval of iberdomide-based therapy in relapsed/refractory multiple myeloma.
www.onclive.com
August 20, 2026 at 5:59 PM
Research from @danafarber.bsky.social helped support this month's FDA approval of Iberdomide-based therapy in relapsed/refractory multiple myeloma #mmsm #oncology www.onclive.com/view/fda-app...
@fda.gov grants Priority Review to iberdomide for #RRMM.
• Target: E3 ligase modulator (CELMoD)
• Phase 3 EXCALIBUR results: Improved PFS
• Target action date: May 2026
Insights via @medicalprofref.bsky.social.
Read the review: https://bit.ly/3Olgg0s
#mmsm #MultipleMyeloma #FDA
• Target: E3 ligase modulator (CELMoD)
• Phase 3 EXCALIBUR results: Improved PFS
• Target action date: May 2026
Insights via @medicalprofref.bsky.social.
Read the review: https://bit.ly/3Olgg0s
#mmsm #MultipleMyeloma #FDA
FDA Grants Priority Review to Iberdomide for Multiple Myeloma - Oncology Nurse Advisor
The NDA is supported by data from the EXCALIBER-RRMM trial, which evaluated the safety and efficacy of iberdomide, an investigational cereblon E3 ligase modulator.
bit.ly
February 21, 2026 at 7:49 PM
@fda.gov grants Priority Review to iberdomide for #RRMM.
• Target: E3 ligase modulator (CELMoD)
• Phase 3 EXCALIBUR results: Improved PFS
• Target action date: May 2026
Insights via @medicalprofref.bsky.social.
Read the review: https://bit.ly/3Olgg0s
#mmsm #MultipleMyeloma #FDA
• Target: E3 ligase modulator (CELMoD)
• Phase 3 EXCALIBUR results: Improved PFS
• Target action date: May 2026
Insights via @medicalprofref.bsky.social.
Read the review: https://bit.ly/3Olgg0s
#mmsm #MultipleMyeloma #FDA
💊#FDA Drug Approvals — August 2026
🔬Notable first-in-class:
• #Daraxonrasib — RAS inhibitor
• Rusfertide — hepcidin mimetic
• Oveporexton — orexin signaling
🧬Other highlights: CELMoD/E3 ligase modulation, Activin A, and JAK/TYK2.
🔬Notable first-in-class:
• #Daraxonrasib — RAS inhibitor
• Rusfertide — hepcidin mimetic
• Oveporexton — orexin signaling
🧬Other highlights: CELMoD/E3 ligase modulation, Activin A, and JAK/TYK2.
September 3, 2026 at 12:10 PM
💊#FDA Drug Approvals — August 2026
🔬Notable first-in-class:
• #Daraxonrasib — RAS inhibitor
• Rusfertide — hepcidin mimetic
• Oveporexton — orexin signaling
🧬Other highlights: CELMoD/E3 ligase modulation, Activin A, and JAK/TYK2.
🔬Notable first-in-class:
• #Daraxonrasib — RAS inhibitor
• Rusfertide — hepcidin mimetic
• Oveporexton — orexin signaling
🧬Other highlights: CELMoD/E3 ligase modulation, Activin A, and JAK/TYK2.
📈Following positive early-phase data for golcadomide, Daniel Morillo, MD, of START-Madrid highlights future directions for the CELMoD in relapsed/refractory follicular lymphoma #lymsm #oncology
Watch now: www.onclive.com/view/dr-mori...
Watch now: www.onclive.com/view/dr-mori...
Dr Morillo on Future Directions for Golcadomide in R/R Follicular Lymphoma | OncLive
Daniel Morillo, MD, discusses future research directions for golcadomide in relapsed/refractory follicular lymphoma.
www.onclive.com
August 25, 2026 at 8:58 PM
📈Following positive early-phase data for golcadomide, Daniel Morillo, MD, of START-Madrid highlights future directions for the CELMoD in relapsed/refractory follicular lymphoma #lymsm #oncology
Watch now: www.onclive.com/view/dr-mori...
Watch now: www.onclive.com/view/dr-mori...
www.biopharmadive.com/news/bristol...
Bristol Myers wins ‘milestone’ FDA approval of myeloma drug acquired from Celgene
Bristol Myers wins ‘milestone’ FDA approval of myeloma drug acquired from Celgene
Bristol Myers wins ‘milestone’ FDA approval of myeloma drug acquired from Celgene
The clearance of Zenbexus is the first for a group of protein-degrading “CELMoD” medicines that could help Bristol Myers rejuvenate a key drug franchise.
www.biopharmadive.com
August 21, 2026 at 12:44 AM
www.biopharmadive.com/news/bristol...
Bristol Myers wins ‘milestone’ FDA approval of myeloma drug acquired from Celgene
Bristol Myers wins ‘milestone’ FDA approval of myeloma drug acquired from Celgene
MRD depth will change launches: MRD-negative CRs may serve as bridge endpoints to introduce new myeloma mechanisms (CELMoD/protein degradation) at first relapse—confirmatory durable outcomes still required. Full breakdown → https://future.xsbrt.com/MyelomaCELMoDFuture Save or reply.
August 20, 2026 at 12:03 AM
MRD depth will change launches: MRD-negative CRs may serve as bridge endpoints to introduce new myeloma mechanisms (CELMoD/protein degradation) at first relapse—confirmatory durable outcomes still required. Full breakdown → https://future.xsbrt.com/MyelomaCELMoDFuture Save or reply.
Hematogenix's Innovative Assay Paves Way for New Multiple Myeloma Treatment Approval#United_States#Multiple_Myeloma#Tinley_Park#Hematogenix#ZENBEXUS
Hematogenix's Innovative Assay Paves Way for New Multiple Myeloma Treatment Approval
Hematogenix's MM MRD assay has played a crucial role in the FDA's accelerated approval of ZENBEXUS, the first CELMoD therapy for multiple myeloma.
third-news.com
August 19, 2026 at 12:48 PM
Hematogenix's Innovative Assay Paves Way for New Multiple Myeloma Treatment Approval#United_States#Multiple_Myeloma#Tinley_Park#Hematogenix#ZENBEXUS
CELMoD research isn't limited to multiple myeloma. Daniel Morillo, MD, of START-Madrid, provides background on the investigational CELMoD golcadomide being evaluated for patients with relasped/refractory follicular lymphoma #lymsm #oncology
Watch now: www.onclive.com/view/dr-mori...
Watch now: www.onclive.com/view/dr-mori...
Dr Morillo on the Mechanism of Action for Golcadomide in R/R Follicular Lymphoma | OncLive
Daniel Morillo, MD, discusses the mechanism of action of golcadomide as a potential treatment for relapsed/refractory follicular lymphoma.
www.onclive.com
August 17, 2026 at 7:26 PM
CELMoD research isn't limited to multiple myeloma. Daniel Morillo, MD, of START-Madrid, provides background on the investigational CELMoD golcadomide being evaluated for patients with relasped/refractory follicular lymphoma #lymsm #oncology
Watch now: www.onclive.com/view/dr-mori...
Watch now: www.onclive.com/view/dr-mori...